TORONTO, April 10, 2013 /CNW/ - Toronto law firm McPhadden Samac Tuovi LLP has commenced a proposed national class action against Boehringer Ingelheim relating to the blood thinner Pradax. The lawsuit is on behalf of all persons throughout Canada who ingested Pradax.
The claim is for damages in the amount of $150,000,000.
Pradax is used to prevent clotting in patients who suffer from atrial fibrillation (a condition in which the heart beats irregularly, increasing the chance of clots forming in the body and possibly causing strokes). It is also used by patients who have had hip and knee surgery.
There have been reports that Pradax causes excessive bleeding. There is no antidote that can be taken to stop excessive bleeding that might be caused by Pradax. Bleeding caused by the drug that Pradax was intended to replace, Warfarin, can easily be stopped using a simple administration of vitamin K.In the lawsuit, it is the plaintiff's position that patients should have been warned about the lack of an antidote. Claims are also made on behalf of others who say they suffered harm because of Pradax. SOURCE McPhadden Samac Tuovi LLP